Displaying all 18 drugs
Trastuzumab
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal...
Approved
Investigational
Matched Synonyms: … Trastuzumab ... trastuzumab-anns ... trastuzumab-dkst …
Matched Name: … Trastuzumab …
Matched Description: … Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and ... In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for ... that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and …
Matched Categories: … pertuzumab and trastuzumab ... trastuzumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ZUHERA Trastuzumab for Injection (rDNA Origin) 150mg/vial ... ZUHERA Trastuzumab for Injection (rDNA Origin) 440 mg/vial ... Herzuma (trastuzumab) 150 mg Powder for Concentrate for Solution for Infusion …
Matched Name: … Trastuzumab …
Matched Description: … Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and ... In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for ... that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and …
Matched Categories: … pertuzumab and trastuzumab ... trastuzumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ZUHERA Trastuzumab for Injection (rDNA Origin) 150mg/vial ... ZUHERA Trastuzumab for Injection (rDNA Origin) 440 mg/vial ... Herzuma (trastuzumab) 150 mg Powder for Concentrate for Solution for Infusion …
Trastuzumab emtansine
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis....
Approved
Investigational
Matched Synonyms: … Ado-trastuzumab ... Trastuzumab-DM1 ... Trastuzumab-MCC-DM1 …
Matched Name: … Trastuzumab emtansine …
Matched Description: … First that trastuzumab emtansine and trastuzumab cannot be interchanged. ... Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive ... , metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease …
Matched Categories: … Trastuzumab ... trastuzumab emtansine ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Name: … Trastuzumab emtansine …
Matched Description: … First that trastuzumab emtansine and trastuzumab cannot be interchanged. ... Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive ... , metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease …
Matched Categories: … Trastuzumab ... trastuzumab emtansine ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Margetuximab
The HER2 oncoprotein, the product of the human ERBB2/mouse neu genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by ERBB2 overexpression, a higher grade, a more...
Approved
Investigational
Matched Description: … induces the same effects as [trastuzumab]. ... increased efficacy compared to [trastuzumab]. ... [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Lapatinib
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Description: … anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and ... Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Neratinib
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pertuzumab
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in...
Approved
Matched Description: … antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. ... It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. ... It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal …
Matched Categories: … pertuzumab and trastuzumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … pertuzumab and trastuzumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Description: … chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Trastuzumab deruxtecan
Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...
Approved
Investigational
Matched Synonyms: … Trastuzumab deruxtecan ... fam-trastuzumab deruxtecan-nxki …
Matched Name: … Trastuzumab deruxtecan …
Matched Description: … and was first approved by the FDA in 2019. ... Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved ... The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from …
Matched Categories: … trastuzumab deruxtecan ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Name: … Trastuzumab deruxtecan …
Matched Description: … and was first approved by the FDA in 2019. ... Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved ... The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from …
Matched Categories: … trastuzumab deruxtecan ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Tucatinib
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who...
Approved
Investigational
Matched Description: … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable ... It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pembrolizumab
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Description: … as interchain bonds and 23 interchain bonds. ... [A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages ... [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Trastuzumab duocarmazine
Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Investigational
Matched Synonyms: … Trastuzumab duocarmazine …
Matched Name: … Trastuzumab duocarmazine …
Matched Description: … Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. …
Matched Categories: … trastuzumab duocarmazine ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Name: … Trastuzumab duocarmazine …
Matched Description: … Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. …
Matched Categories: … trastuzumab duocarmazine ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Zenocutuzumab
Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
Investigational
Matched Synonyms: … Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized ... antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and …
Matched Description: … in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer). ... Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer). ... Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Gancotamab
Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Investigational
Matched Description: … Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. ... Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Inetetamab
Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
Investigational
Matched Description: … It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and ... Inetetamab is a trastuzumab analog. ... possesses an exact F(ab’)2 of trastuzumab. …
A166
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
Matched Description: … cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab …
Elgemtumab
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Investigational
Matched Description: … Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer). ... Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Lorvotuzumab mertansine
Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Investigational
Matched Description: … has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and …
Matched Categories: … Trastuzumab ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Trastuzumab ... Amino Acids, Peptides, and Proteins …
Displaying all 18 drugs